Edgar O. Tapia

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors

J. Schatz, V. Gokhale, Mengdie Wang, 2016, Oncotarget.

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

L. Rimsza, Y. Lussier, W. Liang, 2015, Cancer research.

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.

Winnie S. Liang, L. Rimsza, Y. Lussier, 2015, Cancer research.